All HHS Contracts — June 23, 2026

Only $2.8 million of $141.3 million total has been outlayed, indicating early-stage funding and milestone-based payments. The company is a small, foreign-owned, self-certified small disadvantaged business, raising scalability and investor confidence concerns.

Cost-plus-fixed-fee pricing reduces profit risk for Leidos Holdings, while the contract’s focus on NIAID VRC research aligns with stable federal health spending. Full and open competition win confirms competitive strength.

START2 GROUP’s $141.3M BARDA contract has only $2.8M outlayed, with a 7.5-year performance period. Milestone-based payments and small company size create execution risk; any delays or protest could impair revenue recognition.

Leidos Biomedical Research’s $121.5M NIH contract expires August 2024. If not renewed or followed-on, Leidos loses ~$30.4M annual revenue from this specific award, though impact is modest relative to total revenue.

Leidos’ competitive win at NIH under full and open competition signals potential for follow-on awards in health R&D, particularly in vaccine research (NIAID VRC). Stable NIH funding supports contract renewal.

START2 GROUP’s $141.3M BARDA contract, if executed successfully, could transform the company’s revenue base (current annual revenue est. $18.8M). Milestone payments may accelerate as program progresses.

Both contracts are from HHS (BARDA and NIH), totaling $262.8M, indicating sustained federal investment in biodefense and cancer/vaccine research despite budget uncertainty. No defense exposure reduces CR risk.

{"entity"=>"Leidos Holdings, Inc.", "reason"=>"NIH contract expires August 2024; renewal or follow-on will impact health R&D revenue stream.", "trigger"=>"Re-compete announcement or option exercise for $4.3M remaining options"}

{"entity"=>"START2 GROUP, INC.", "reason"=>"Only $2.8M outlayed on $141.3M contract; execution pace is critical for revenue recognition.", "trigger"=>"Quarterly outlayed amount updates or contract modification filings"}